This HTML5 document contains 156 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/mixture/
n30http://www.drugs.com/
n27http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n16http://www.rxlist.com/cgi/generic/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/pharmgkb/
n28http://linked.opendata.cz/resource/drugbank/patent/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/bindingdb/
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/ontology/mesh/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00697/identifier/drugbank/
n29http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00697
rdf:type
n3:Drug
n3:description
Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
n3:dosage
n8:271B485B-363D-11E5-9242-09173F13E4C5 n8:271B485C-363D-11E5-9242-09173F13E4C5 n8:271B485D-363D-11E5-9242-09173F13E4C5 n8:271B485E-363D-11E5-9242-09173F13E4C5 n8:271B485F-363D-11E5-9242-09173F13E4C5 n8:271B4857-363D-11E5-9242-09173F13E4C5 n8:271B4858-363D-11E5-9242-09173F13E4C5 n8:271B4859-363D-11E5-9242-09173F13E4C5 n8:271B485A-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2.5 hours
n3:indication
For the management of increased muscle tone associated with spasticity
n3:manufacturer
n4:271B484D-363D-11E5-9242-09173F13E4C5 n4:271B484A-363D-11E5-9242-09173F13E4C5 n4:271B484B-363D-11E5-9242-09173F13E4C5 n4:271B4848-363D-11E5-9242-09173F13E4C5 n4:271B4849-363D-11E5-9242-09173F13E4C5 n4:271B4846-363D-11E5-9242-09173F13E4C5 n4:271B4847-363D-11E5-9242-09173F13E4C5 n4:271B484E-363D-11E5-9242-09173F13E4C5 n4:271B484F-363D-11E5-9242-09173F13E4C5 n4:271B4844-363D-11E5-9242-09173F13E4C5 n4:271B4845-363D-11E5-9242-09173F13E4C5 n4:271B4843-363D-11E5-9242-09173F13E4C5 n4:271B484C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n25:DB00697 n27:DB00697
dcterms:title
Tizanidine
adms:identifier
n11:PA451701 n12:Tizanidine n18:50240671 n19:5287 n20:5487 n21:46505373 n22:C07452 n23:0378-0722-01 n26:DB00697
n3:mechanismOfAction
Tizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites.
n3:packager
n4:271B4818-363D-11E5-9242-09173F13E4C5 n4:271B4819-363D-11E5-9242-09173F13E4C5 n4:271B4816-363D-11E5-9242-09173F13E4C5 n4:271B4817-363D-11E5-9242-09173F13E4C5 n4:271B481C-363D-11E5-9242-09173F13E4C5 n4:271B481D-363D-11E5-9242-09173F13E4C5 n4:271B481A-363D-11E5-9242-09173F13E4C5 n4:271B481B-363D-11E5-9242-09173F13E4C5 n4:271B4815-363D-11E5-9242-09173F13E4C5 n4:271B4838-363D-11E5-9242-09173F13E4C5 n4:271B4839-363D-11E5-9242-09173F13E4C5 n4:271B4836-363D-11E5-9242-09173F13E4C5 n4:271B4837-363D-11E5-9242-09173F13E4C5 n4:271B483C-363D-11E5-9242-09173F13E4C5 n4:271B483D-363D-11E5-9242-09173F13E4C5 n4:271B483A-363D-11E5-9242-09173F13E4C5 n4:271B483B-363D-11E5-9242-09173F13E4C5 n4:271B4830-363D-11E5-9242-09173F13E4C5 n4:271B4831-363D-11E5-9242-09173F13E4C5 n4:271B482E-363D-11E5-9242-09173F13E4C5 n4:271B482F-363D-11E5-9242-09173F13E4C5 n4:271B4834-363D-11E5-9242-09173F13E4C5 n4:271B4835-363D-11E5-9242-09173F13E4C5 n4:271B4832-363D-11E5-9242-09173F13E4C5 n4:271B4833-363D-11E5-9242-09173F13E4C5 n4:271B4828-363D-11E5-9242-09173F13E4C5 n4:271B4829-363D-11E5-9242-09173F13E4C5 n4:271B4826-363D-11E5-9242-09173F13E4C5 n4:271B4827-363D-11E5-9242-09173F13E4C5 n4:271B482C-363D-11E5-9242-09173F13E4C5 n4:271B482D-363D-11E5-9242-09173F13E4C5 n4:271B482A-363D-11E5-9242-09173F13E4C5 n4:271B482B-363D-11E5-9242-09173F13E4C5 n4:271B4820-363D-11E5-9242-09173F13E4C5 n4:271B4821-363D-11E5-9242-09173F13E4C5 n4:271B481E-363D-11E5-9242-09173F13E4C5 n4:271B481F-363D-11E5-9242-09173F13E4C5 n4:271B4824-363D-11E5-9242-09173F13E4C5 n4:271B4825-363D-11E5-9242-09173F13E4C5 n4:271B4822-363D-11E5-9242-09173F13E4C5 n4:271B4823-363D-11E5-9242-09173F13E4C5 n4:271B4840-363D-11E5-9242-09173F13E4C5 n4:271B4841-363D-11E5-9242-09173F13E4C5 n4:271B483E-363D-11E5-9242-09173F13E4C5 n4:271B483F-363D-11E5-9242-09173F13E4C5 n4:271B4842-363D-11E5-9242-09173F13E4C5
n3:patent
n28:6455557
n3:routeOfElimination
Approximately 95% of an administered dose is metabolized.
n3:synonym
Tizanidine Tizanidinum 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole Tizanidin Tizanidina
n3:volumeOfDistribution
* 2.4 L/kg
n5:hasAHFSCode
n6:12-20-00
n3:mixture
n7:271B4803-363D-11E5-9242-09173F13E4C5 n7:271B4814-363D-11E5-9242-09173F13E4C5 n7:271B480A-363D-11E5-9242-09173F13E4C5 n7:271B480B-363D-11E5-9242-09173F13E4C5 n7:271B4808-363D-11E5-9242-09173F13E4C5 n7:271B4809-363D-11E5-9242-09173F13E4C5 n7:271B4806-363D-11E5-9242-09173F13E4C5 n7:271B4807-363D-11E5-9242-09173F13E4C5 n7:271B4804-363D-11E5-9242-09173F13E4C5 n7:271B4805-363D-11E5-9242-09173F13E4C5 n7:271B4812-363D-11E5-9242-09173F13E4C5 n7:271B4813-363D-11E5-9242-09173F13E4C5 n7:271B4810-363D-11E5-9242-09173F13E4C5 n7:271B4811-363D-11E5-9242-09173F13E4C5 n7:271B480E-363D-11E5-9242-09173F13E4C5 n7:271B480F-363D-11E5-9242-09173F13E4C5 n7:271B480C-363D-11E5-9242-09173F13E4C5 n7:271B480D-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
30%
n3:salt
n3:synthesisReference
Pavel Hradil, Lubomir Kvapil, Martin Grepl, Jan Novotny, "METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE." U.S. Patent US20110263863, issued October 27, 2011.
n13:hasConcept
n14:M0081344
foaf:page
n16:tizanidine.htm n30:tizanidine.html
n3:IUPAC-Name
n9:271B4864-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B486A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B4869-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B4866-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B4867-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B4868-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B4862-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B4879-363D-11E5-9242-09173F13E4C5 n9:271B4860-363D-11E5-9242-09173F13E4C5 n9:271B4863-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B4861-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n29:M03BX02
n3:H-Bond-Acceptor-Count
n9:271B4870-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B4871-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B486B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B486C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B486E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B486D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B486F-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51322-75-9
n3:category
n3:containedIn
n17:271B4851-363D-11E5-9242-09173F13E4C5 n17:271B4852-363D-11E5-9242-09173F13E4C5 n17:271B4850-363D-11E5-9242-09173F13E4C5 n17:271B4855-363D-11E5-9242-09173F13E4C5 n17:271B4856-363D-11E5-9242-09173F13E4C5 n17:271B4853-363D-11E5-9242-09173F13E4C5 n17:271B4854-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n9:271B4875-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B4877-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B4878-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B4874-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B4873-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B4876-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B4865-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B4872-363D-11E5-9242-09173F13E4C5